✦ LIBER ✦

Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea

✍ Scribed by Eui-Kyung Lee; Cedric Revil; Charles A. Ngoh; Johanna Lister; Jeong-Mi Kwon; Mee-Hye Park; Seok-Jin Park; Young-Suk Park; Sang-Joon Shin; Myung-Ah Lee; Nam-Su Lee; Dae-Young Zang; Eun-Jin Bae; Mi-Jeong Kang

Book ID: 113544706
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 460 KB
Volume: 34
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2012.05.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN69 COST-EFFECTIVENESS OF FIRST-LINE C

PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

✍ M Gyldmark; R Aultman; U Siebert; E Sabate 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

The Clinical Efficacy of FOLFIRI and Bev

The Clinical Efficacy of FOLFIRI and Bevacizumab in Combination as First-Line Therapy of Metastatic Colorectal Cancer

✍ Erin Grothey; Edward Chu 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 91 KB

An observational study of bevacizumab co

An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer

✍ Huang, Meng-Lin; Kan, Jung-Yu; Ma, Cheng-Jen; Huang, Ching-Wen; Chen, Fang-Ming; 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 261 KB

O-0029 * FOLFIRI PLUS CETUXIMAB VERSUS F

O-0029 * FOLFIRI PLUS CETUXIMAB VERSUS FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF KRAS-WILDTYPE METASTATIC COLORECTAL CANCER: GERMAN AIO STUDY KRK-0306 (FIRE-3)

✍ Modest, D.; von Weikersthal, L. F.; Stintzing, S.; Decker, T.; Kiani, A.; Vehlin 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 33 KB

A retrospective observational study on t

A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer

✍ López, R; Salgado, M; Reboredo, M; Grande, C; Méndez, J C; Jorge, M; Romero, C; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 320 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

✍ Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jage 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 225 KB